Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States
about
Cost-Effectiveness of HBV and HCV Screening Strategies--A Systematic Review of Existing Modelling TechniquesEconomic evaluation of screening programs for hepatitis C virus infection: evidence from literatureWhy equal treatment is not always equitable: the impact of existing ethnic health inequalities in cost-effectiveness modeling.Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsSofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysisCost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.Cost-effectiveness of screening for hepatitis C in Canada.Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesComparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus.Age-period-cohort analysis of infectious disease mortality in urban-rural China, 1990-2010.Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment.Population-level intervention and information collection in dynamic healthcare policy.In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics.Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST-C study.The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.Birth year distribution in reported hepatitis C cases in Switzerland.Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.Economic evaluation of HCV testing approaches in low and middle income countries.Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.Hepatitis C Screening of the "Birth Cohort" (Born 1945-1965) and Younger Inmates of New York City Jails.Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based EvidenceHepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment
P2860
Q26774500-9A85EE2C-A17C-4EF8-BCEA-86792E62F464Q26998567-F18BC8A5-F68B-44E5-894C-280CB083C868Q33719771-A7E7CD43-7A9F-4FC7-B767-0C08D05E8492Q34735072-262C3055-02A5-4C3F-90BF-B6312510B945Q35037688-1563FAE9-E3D0-4A75-ACA2-11796C404B62Q35058571-396740B5-5EE1-497D-81A6-D7670328A4CBQ35088460-534056A0-4528-4F92-AD40-DA600AE075F9Q35619161-9713EAC2-495B-4FEC-BD19-C1399484D837Q35935659-D4C6CF7A-E066-493F-BFC9-5C7899CB04D2Q36748876-2F05F7B7-9953-4385-A1A5-A53E5DFD91B5Q36862066-8C0C5FDA-AD16-4AB7-A001-2EA5C1D66F6FQ37251861-97366BDE-79FD-4F22-BCD0-605A261A45FFQ38983274-B9B011F0-24BD-4904-877A-CFB18B9C886EQ40049914-790E2B72-B0C2-4E0B-8928-D42CC90E8536Q40118666-BFD5C390-79F6-4755-B38F-C16B2B97B02DQ40168920-EBB9FDDD-CAF7-4453-B1A0-A24F01849C8FQ40524477-BA482903-9F92-4C4C-AA26-00F0AFBCF425Q41207230-5B7915A8-33CA-405F-A9DD-80E1E625F5CAQ42048758-BCF22474-D6D5-4328-AFCC-F816FCD27A1FQ42203865-49EC29D7-5629-4C53-8A66-BE3D554B55BFQ42227512-061B834C-5A65-4D2E-9B74-3A873A6E716AQ46983780-4346FFDB-5B44-4337-9F0B-B14BB5DE0541Q47603693-E3A6AB30-9C53-436C-8C3A-AC983A06C669Q54593526-F24988DF-280E-47A3-A8EC-52E50CAACAA0Q57145115-B3D49B1E-6731-4C9C-B2D5-F3A10DA36AF7Q57167190-E80BC8B6-8B02-4EFB-A906-DAA187CE3693
P2860
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Cost-effectiveness analysis of ...... infection in the United States
@ast
Cost-effectiveness analysis of ...... infection in the United States
@en
Cost-effectiveness analysis of ...... infection in the United States
@nl
type
label
Cost-effectiveness analysis of ...... infection in the United States
@ast
Cost-effectiveness analysis of ...... infection in the United States
@en
Cost-effectiveness analysis of ...... infection in the United States
@nl
prefLabel
Cost-effectiveness analysis of ...... infection in the United States
@ast
Cost-effectiveness analysis of ...... infection in the United States
@en
Cost-effectiveness analysis of ...... infection in the United States
@nl
P2860
P50
P3181
P1433
P1476
Cost-effectiveness analysis of ...... infection in the United States
@en
P2093
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0058975
P407
P577
2013-01-01T00:00:00Z